UFH is the Most Used Anticoagulant in Hemodialysis, Decreasing the Risk of Clot Formation in the Circuit.

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study was to verify the clinical non-inferiority of the pharmacodynamic effects and the safety of use of the drug Heptar® manufactured by Eurofarma Laboratory, compared to the drug Liquemine®, manufactured by by Roche Laboratory in patients with renal failure undergoing hemodialysis treatment

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eurofarma Laboratorios S.A.
• Treatments: Heparin

Criteria

Inclusion Criteria:

• Adults of both sexes, regardless of color or social class;

• Age over 18 years, with good clinical characteristics at medical discretion;

• Research patients who agree to participate in the study and sign the consent form free and informed;

• Chronic renal failure patients on dialysis regimen (3 times a week).

• Chronic Kidney Failure with indication for anticoagulant during dialysis

Exclusion Criteria:

• Not agreeing with the terms described in the informed consent;

• Research patients with sensitivity to sadistic heparin;

• Research patients with hypersensitivity to benzyl alcohol;

• Research patients with a history of bleeding or disease that change in coagulation may worsen or terminate the clinical picture, such as ulcer gastric;

• Research patients with a history of peptic ulcer.